OTCMKTS:VACBF Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free VACBF Stock Alerts $1.50 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.5050-Day Range$1.25▼$1.5852-Week Range$1.25▼$1.58VolumeN/AAverage Volume3,500 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartShort InterestStock AnalysisAnalyst ForecastsChartShort Interest Get Nykode Therapeutics AS alerts: Email Address Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Nykode Therapeutics ASNykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.Read More VACBF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VACBF Stock News HeadlinesMay 14 at 1:15 AM | globenewswire.comNykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical CancerMay 14 at 1:00 AM | globenewswire.comNykode Therapeutics - Quarterly report Q1 2024April 19, 2024 | globenewswire.comNykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical CancerMarch 21, 2024 | globenewswire.comNykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical CancerMarch 19, 2024 | globenewswire.comNykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune DiseasesJanuary 29, 2024 | finance.yahoo.comNykode Therapeutics - Quarterly report Q3 2023See More Headlines Receive VACBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nykode Therapeutics AS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/16/2024Next Earnings (Estimated)5/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:VACBF CUSIPN/A CIKN/A Webnykode.com Phone47-22-95-81-93FaxN/AEmployees171Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael Thyring Engsig (Age 52)Chief Executive Officer Comp: $567kDr. Agnete B. Fredriksen Ph.D. (Age 47)Chief Scientific Officer & Co-founder Mr. Harald Gurvin (Age 49)Chief Financial Officer Mr. Ulrich BlaschkeChief Technology OfficerMs. Louise StubbeChief Legal OfficerDr. Klaus Edvardsen M.D. (Age 61)Ph.D., Chief Research & Development Officer More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors VACBF Stock Analysis - Frequently Asked Questions Should I buy or sell Nykode Therapeutics AS stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nykode Therapeutics AS in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VACBF shares. View VACBF analyst ratings or view top-rated stocks. How have VACBF shares performed in 2024? Nykode Therapeutics AS's stock was trading at $1.58 on January 1st, 2024. Since then, VACBF stock has decreased by 5.1% and is now trading at $1.50. View the best growth stocks for 2024 here. How do I buy shares of Nykode Therapeutics AS? Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VACBF) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldGold Set to EXPLODE!Gold Safe ExchangeDoes this make you sick?Allegiance GoldUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate CapitalHow Biden has already won 2024Porter & Company348 million Americans lives to END as we know it?The Oxford ClubBiden Nomination CANCELED?The Freeport SocietyUrgent: They're Coming for Your Retirement Money Next!Lear Capital Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nykode Therapeutics AS Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.